AMNEAL PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 |
|---|---|---|---|
| Revenue | $1.66B | $1.03B | $1.02B |
| Cost of Revenue | $938.8M | $507.5M | $420.8M |
| Gross Profit | $716.4M | $526.2M | $597.5M |
| Gross Margin | 43.1% | 50.9% | 58.7% |
| Operating Expenses | |||
| Research & Development | $194.2M | $171.4M | $179.0M |
| SG&A Expense | $227.8M | $109.0M | $118.8M |
| Operating Income | $-19.7M | $245.1M | $284.9M |
| Operating Margin | -1.2% | 23.7% | 28.0% |
| Interest Expense | — | — | — |
| Pretax Income | $-202.7M | $171.3M | $214.8M |
| Income Tax Expense | $-1.4M | $2.0M | $5.4M |
| Net Income | $-19.7M | $0 | $0 |
| Net Margin | -1.2% | 0.0% | 0.0% |
| EPS (Basic) | $-0.16 | — | — |
| EPS (Diluted) | $-0.16 | — | — |
| Shares Outstanding (Basic) | 127.3M | 1.0K | — |
| Shares Outstanding (Diluted) | 127.3M | 1.0K | — |
| Dividends Per Share | — | — | — |